# Lorlatinib Compared with Concurrent/ Sequential Chemoradiotherapy in Stage III ALK Positive Lung Adenocarcinoma

Source: https://onco.cc/trials/nct06858410/  
OnCo record `nct06858410` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of lorlatinib in lung cancer, run by Guangdong Association of Clinical Trials, not yet recruiting.

## Summary

Lorlatinib Compared with Concurrent/ Sequential Chemoradiotherapy in Stage III ALK Positive Lung Adenocarcinoma is a phase 3, randomised interventional study registered as NCT06858410 by Guangdong Association of Clinical Trials, with a registry enrolment figure of 36 participants, started 2025-03 and due to reach its primary completion in 2030-03. Interventions recorded: lorlatinib; concurrent/sequential platinum-based chemoradiotherapy. Conditions listed: Neoadjuvant Non-Small Cell Lung Cancer. Primary outcome: Progression Free Survival (PFS). Lung eligibility wording from the registry: "* Study Population: Patients with histologically or cytologically confirmed diagnosis of ALK-positive, lung adenocarcinoma who present with locally advanced, unresectable (Stage III) disease (according to Version 8 of the International Association for the Study of Lung Cancer \[IASLC\])". No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-25
- Tags: ctgov-ingest; lung-deep-dive
- Registry id: NCT06858410
- Phase: 3
- Setting: A Randomized, Open-label, Multicenter, Phase III Study of Lorlatinib Compared with Concurrent/ Sequential Chemoradiotherapy As Definitive Treatment in Patients with Locally Advanced, Unresectable Stage III ALK Positive Lung Adenocarcinoma
- Sponsor: Guangdong Association of Clinical Trials
- Enrolled: 36

## Sources

- ClinicalTrials.gov NCT06858410: https://clinicaltrials.gov/study/NCT06858410

## Connected records

- cancers: [ALK-positive non-small-cell lung cancer](https://onco.cc/cancers/alk-positive-nsclc/), [Unresectable stage III non-small-cell lung cancer](https://onco.cc/cancers/stage-iii-unresectable-nsclc/)
- technologies: [IMRT / IGRT (modern external beam)](https://onco.cc/technologies/imrt-igrt/), [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/)
- drugs: [Lorlatinib](https://onco.cc/drugs/lorlatinib/)
- terms: [Lung cancer trials open today (registry snapshot)](https://onco.cc/terms/lung-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06858410.json